BTIG analysts said today that MiniMed, the Medtronic (NYSE:MDT) diabetes business, has some significant pipeline updates. Marie Thibault, Sam Eiber and Alexandra Pang shared notes from their meeting with Que Dallara, soon-to-be CEO of the to-be separated Diabetes unit, at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Among those updates, the company expects […]
Medtronic
Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients. The medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in Chicago. In one study, participants […]
Medtronic to invest $50M in India Diabetes center
Medtronic (NYSE:MDT) announced that it inaugurated a new Diabetes Global Capability Center in India with a significant investment. The medtech giant said it plans to invest $50 million over five years in the Pune, India location. In a post on LinkedIn, Medtronic said: “We are proud to mark a significant milestone with the inauguration of […]
Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
Medtronic (NYSE:MDT) announced today that it selected “MiniMed” as the name for its Diabetes unit following its planned separation. The medtech giant announced last month that it planned to separate the Diabetes unit. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, […]
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
Medtronic announced today that it received CE mark for several expanded indications for its Prevail balloon catheter. The expanded indications for the paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (or drug-coated balloon/DCB) cover the treatment of coronary artery disease (CAD). According to the medtech giant, Prevail now has the broadest range of CE mark […]
Medtronic to separate Diabetes business unit
Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]
Medtronic Diabetes adds former Moderna exec as chief marketing officer
Medtronic (NYSE:MDT) announced today that it appointed Kate Cronin as the new chief marketing officer for its Diabetes unit. Cronin previously served as chief brand & corporate affairs officer at Moderna. Medtronic says she brings experience in global brand strategy, consumer marketing, corporate communications, public affairs and employee engagement. This marks yet another significant leadership move […]
Medtronic submits interoperable insulin pump to FDA to advance collaboration with Abbott
Medtronic (NYSE:MDT) announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable insulin pump. Clearance would enable system integration with a continuous glucose monitor (CGM) sensor based on Abbott’s most advanced platform. This marks the latest development in a landmark collaboration between the two medtech giants. Last summer, the companies […]
Medtronic wins FDA nod for new Simplera Sync CGM with MiniMed 780G
Medtronic (NYSE:MDT) announced that the FDA approved its Simplera Sync continuous glucose monitor for use with the MiniMed 780G. Approval provides more options for users of the automated insulin delivery (AID) system, which can also work with the Guardian 4 sensor. Simplera Sync, a disposable, all-in-one sensor requires no fingersticks or overtape. It works with SmartGuard […]
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
